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Migraine onset is associated with the abnormal release of vasoactive neurotransmitters from perivascular nerves, and these
neurotransmitters are involved in the pathophysiology of migraine. Hyperalgesia is a key feature of migraine, and accumulating
evidence indicates that electroacupuncture (EA) at the single acupuncture point (Fengchi [GB20]) is effective in ameliorating
hyperalgesia. In clinical practice,multiple acupuncture points arewidely used, especiallyGB20 andYanglingquan (GB34).However,
the role played by vasoactive neurotransmitters in acupuncture antihyperalgesic effect at the single or multiple acupuncture
points remains unknown. We aimed to determine whether EA would exert its antihyperalgesic effects by modulating vasoactive
neurotransmitter release from the perivascular nerves. Furthermore, we examined whether targeting multiple acupuncture points
would be more effective than targeting a single point in reducing hyperalgesia. The mechanical and thermal hyperalgesia were
evaluated by measuring the facial and hind-paw mechanical withdrawal thresholds, tail-flick and hot-plate latencies. Plasma
concentrations of vasoactive neurotransmitters were determined using rat-specific ELISA kits from jugular vein, including
calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), pituitary
adenylate cyclase-activating polypeptide (PACAP), nitric oxide (NO), and endothelin-1 (ET-1). The result suggested that EA
significantly ameliorated the mechanical and thermal hyperalgesia, reduced c-Fos levels in the trigeminal ganglion, and attenuated
plasma and dural levels of vasoactive neurotransmitters, especially in the multiple acupuncture points group (GB20+GB34). In
conclusion, EA exerts antihyperalgesic effect in a rat model of conscious recurrent migraine, possibly via modulation of the
vasoactive neurotransmitters. Furthermore, targeting multiple acupuncture points is more effective than targeting a single point in
reducing hyperalgesia.
Hindawi
Evidence-Based Complementary and Alternative Medicine
Volume 2019, Article ID 9512875, 14 pages
https://doi.org/10.1155/2019/9512875
2 Evidence-Based Complementary and Alternative Medicine
1. Introduction
Migraine is a perplexing, essentially inherited, and variable
disorder of brain function that affects one in nine adults
worldwide [1, 2]. It significantly affects an individual’s quality
of life [3], especially during peak years of productivity. Hyper-
algesia or cutaneous allodynia, which refers to pain provoked
by nonnociceptive stimulation, affects 39.9% of migraineurs
[4].The dysfunctional neurovascular interactions play a pivot
role in migraine onset phase.
Previous studies have suggested that vasodilation and
contraction are associated with the development of migraine
[5–8]. During the attack, a previous study has found that
the contraction of extracerebral arteries is associated with
the amelioration of headache [9]; and during the headache-
free periods, it was found that the intracranial cerebral blood
flow increases (vasodilatation) [10]. Moreover, during the
migraine attack and the headache-free periods, the vasodilat-
ing neurotransmitters are elevated in the plasma, including
calcitonin gene-related peptides (CGRP) [11], substance P
(SP) [12, 13], vasoactive intestinal peptide (VIP) [14, 15], and
nitric oxide (NO) [16]. At the same time, the vasoconstrictive
neurotransmitters counteract a possible migraine-induced
dilation. During the migraine attack, plasma neuropeptide Y
(NPY) [17] and endothelin-1 (ET-1) level [18] are significantly
increased relative to the levels in healthy individuals, while
during the headache-free periods, the ET-1 level is signifi-
cantly increased relative to the level in healthy individuals
[18] and the plasma NPY level [19] is not significantly altered.
These vasoconstrictive neurotransmitters are also important
for regulating the peripheral and central circulation [20],
leading to activation and sensitization of the trigeminovas-
cular system (TS) (Figure 1(a)) [21–23].
A recent study has also shown that intracerebral vasodi-
latation is positively correlated with headache frequency
and the number of cutaneous allodynia symptoms [10].
Cutaneous allodynia or hyperalgesia, which is defined as the
perception of pain or discomfort in response to innocuous
thermal (heat or cold) and/or mechanical (static or dynamic)
stimuli, has been recognized as a clinical manifestation of
central sensitization inmigraine patients [24]. Furthermore, a
preclinical experiment has suggested that the levels of vasoac-
tive neurotransmitters CGRP and pituitary adenylate cyclase-
activating polypeptide (PACAP) are dynamically elevated in
the trigeminal ganglion (TG), and facial mechanical with-
drawal threshold (MWT) gradually decreases as the number
of dural electrical stimulations (DES) increases [5].Therefore,
these vasoactive neurotransmitters are key mediators in the
pathophysiology of migraine [25, 26].
Acupuncture is known to be effective for alleviating
pain and cutaneous allodynia and for preventing recurrent
migraine [27, 28]. In our previous studies, we demon-
strated that acupuncture could effectively alleviate mechan-
ical hyperalgesia and normalizes the levels of abnormal
biomarkers (c-Fos, CGRP, and serotonin [5-HT]) [29–
31]. However, the peripheral trigeminovascular system has
received little attention, especially with respect to vasoactive
neurotransmitters and specific dural perivascular nerves. In
addition, most previously preclinical studies utilized a single
acupuncture point (e.g., GB20 [Fengchi]) for the treatment
of migraine [29–31]. However, multiple acupuncture points
are often used in clinical practice (e.g., GB20 and Yan-
glingquan [GB34]) [28, 32–35]. Therefore, the present study
had two main aims. First, using a rat model of conscious
recurrent migraine, we sought to determine whether elec-
troacupuncture (EA) would exert an antihyperalgesic effect
by modulating vasoactive neurotransmitter release from the
dural perivascular nerves. Second, we examined whether
acupuncture at multiple points would be more effective than
that of a single point in attenuating hyperalgesia.
2. Methods
2.1. Animals. The present study was approved by the Institu-
tional Review Board for Animal Experiments at CapitalMed-
ical University (approval number: AEEI 2015-075). Surgeries
were performed under general anesthesia, and all possible
efforts were made to minimize suffering. 60 eight-week-old
male, specific-pathogen-free Sprague Dawley rats (Academy
of Military Medical Sciences, SCXK-PLA 201200004, Chi-
nese People’s Liberation Army, China), weighing 210 ± 10
g, were used in this study. Rats were housed in groups of
four in cages (64 cm × 40 cm × 22 cm) for 1 week prior
to undergoing brain surgery, and then they were housed
individually following electrode implantation. All animals
were housed in an ambient laboratory environment (room
temperature: 22∘C; humidity: 40%-60%) and had free access
to food and water, and were housed under a 12-h light/dark
cycle.
2.2. Surgical Procedures. As described in a previous study
[36], rats were anesthetized via an intraperitoneal injection
of 60 mg/kg pentobarbital sodium (Sigma-Aldrich, St. Louis,
MO,USA). Twoholes (approximately 1mm indiameter)were
drilled using a dental drill (78001; RWD Life Science, Shen-
zhen, Guangdong Province, China). The drill was positioned
4 mm anterior and 6 mm posterior to the bregma and the
midline, respectively. The cranial holes were located over the
dura mater around the superior sagittal sinus (SSS). All rats
were allowed a 7-day recovery period prior to the DES and
EA treatment.
2.3. Animal Groups. Based on methods used previously
[29], we included 10 animals in each group. After surgery,
60 animals were randomly divided into the following six
groups: a sham-operated (Sham) group, which underwent
electrode implantation only; a model (Model) group, which
received DES only; a nonacupuncture point (Non-Acu)
group, which included DES rats that received EA at a
distant nonacupuncture point [37] (approximately 10 mm
above the iliac crest); and GB20+GB34, GB20, and GB34
groups afterDES, respectively. According to theWorldHealth
Organization Standard Acupuncture Point Locations (World
Health Organization Regional Office for the Western Pacific,
2008), GB20 is located “in the anterior region of the neck,
inferior to the occipital bone, in the depression between
the origins of the sternocleidomastoid and the trapezius
muscles.” The anatomical position of GB20 in the rat is
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Figure 1: Overview of the dura mater and its associated constituents and diagram of the experimental protocol. (a) Overview of the dural
vessels, perivascular nerves, and neurotransmitters. CGRP: calcitonin gene-related peptide; PACAP: pituitary adenylate cyclase-activating
polypeptide; NO: nitric oxide; SP: substance P; NPY: neuropeptide Y; VIP: vasoactive intestinal peptide; ET-1: endothelin-1. (b) Rat schematic
showing the location of the acupuncture points used in the present study. GB20: Fengchi, GB34: Yanglingquan; Non-Acu: nonacupuncture
point. (c) Photograph of a conscious rat with a wire connection through the rubber tubing between the electrode and an electrical stimulator.
(d) Rats received dural electrical stimulation (DES) every other day from Day 1 to Day 7 (on Days 1, 3, 5, and 7). Electroacupuncture (or
nonacupuncture point acupuncture) was performed daily from Day 1 to Day 7 in each group following the DES. On the 7th day (Day 0)
after surgery and the next day following the final DES session (Day 8), baseline and postintervention withdrawal thresholds were measured
in conscious rats. On Days 1, 3, 5, and 7, facial and hind-paw withdrawal thresholds, tail-flick, and hot-plate latencies were measured in
conscious rats following EA treatment. Tissue samples were collected after the final behavioral test.
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located 3 mm from the midpoint of the two ear connecting
lines behind the head [29].The ratGB34,which is determined
according to the GB34 position in humans, is located at the
depression anterior and inferior to the head of the fibula
[38, 39] (Figure 1(b)).
2.4. Induction of Recurrent Conscious Migraine in Rats via
DES. The experiment started after recovery period and
lasted for 8 days. DES was administered to the Non-
Acu, GB20+GB34, GB20, GB34 and Model groups using a
stimulator (YC-2 stimulator; Chengdu Instrument Factory,
Chengdu, Sichuan Province, China) in conscious rats. In
accordance with methods described previously, DES, which
consisted of 0.5 msmonophasic square wave pulses of 1.8–2.0
mA (intensity) and 20 Hz (frequency), was administered to
rats for a 15 min period every other day (on Days 1, 3, 5, and
7), for a total of four sessions [31] (Figure 1(c)).
2.5. EA Treatment. EA was applied at a frequency of 2/15
Hz (amplitude-modulated wave) and an intensity of 0.5–1.0
mA (depending on the reaction of the rat) for 15 min
without anesthesia. From Day 1 to Day 7, the Non-Acu,
GB20+GB34, GB20, and GB34 groups received EA following
electrical stimulation for a total of seven sessions. Stainless-
steel acupuncture needles (25 mm × 0.25 mm; Suzhou
Medical Appliance Factory, Suzhou, Jiangsu Province, China)
were bilaterally inserted intoGB20 andGB34 at a depth of 2–3
mm (Figure 1(b)). However, in the Sham and Model groups,
rats were held for 15 min, but no EA was applied.
2.6. Behavioral Testing of the Hyperalgesia Response. Accord-
ing to previous studies, decreases in the MWT and thermal
withdrawal threshold (TWT) indicate the presence of hyper-
algesia [31, 40]. The MWT can be measured using a von Frey
anesthesiometer [31, 40], while the TWT can bemeasured via
the hot-plate [41] and the tail-flick test [42]. In this study, an
electronic von Frey anesthesiometer (Model 2390; IITC Life
Science, Woodland Hills, CA, USA) was used to measure the
facial (midline of the forehead) andhind-paw (plantar aspect)
withdrawal thresholds. The pain response to thermal stimuli
was assessed using the tail-flick and hot-plate analgesia meter
(Yiyan Technology Development Co., Ltd., Jinan, Shandong
Province, China). Measurements were performed at least 24
h before the experiment (baseline on Day 0), 0.5 h after
treatment sessions (on Days 1, 3, 5, and 7), and 24 h after the
last treatment session (on Day 8) (Figure 1(d)). All tests were
performed in awake and freely moving animals, without any
sedation. The experiment was evaluated by an investigator
blinded to the experimental groups. A different investigator
conducted the experiments [43].
Rats were first acclimated to the experimental environ-
ment and innocuousmechanical stimulation for 3 days before
electrode implantation. The von Frey anesthesiometer probe
was applied vertically to the skin of the face or hind-paw until
the rat made an escapemovement.When the escape response
occurred, themaximum forcewas recorded as thewithdrawal
threshold. In accordance with preliminary observations and
previous studies, rats with forces of <8 g [43] and >60 g [44]
for the facialMWTand<15 g [43] and>60 g [44] for the hind-
paw MWT at baseline were excluded from further analyses.
2.6.1. Facial Hyperalgesia. Rats were placed in a tailored
plastic restraint tube (length, 25 cm; inner diameter, 8
cm) with a mesh inlay at the front, which enabled easy
access to the periorbital region. After a 30-min habituation
period, the von Frey anesthesiometer tip was applied to the
periorbital regionwith steady vertical pressure until an escape
movement occurred. A total of three trials were completed at
30-s intervals. The mean value from all trials was considered
the facial MWT.
2.6.2. Hind-Paw Hyperalgesia. Rats were placed separately
under transparent plastic boxes on an elevatedmesh platform
for 30 min.The von Frey anesthesiometry probe was inserted
through the mesh to prod the hind-paw until the paw was
withdrawn from the tip or lifted off the mesh floor. The assay
was performed three times at 30-second intervals. The mean
value from all trials was considered the hind-paw MWT.
2.6.3. Tail-Flick Latency. Rats were placed separately in a
rat frame for 30 min. Briefly, radiant heat was applied
approximately 4 cm from the tip of the animal’s tail. The
intensity of the thermal stimulus was adjusted to provide an
average baseline tail-flick latency of 3–4 s. A cut-off time of
16 s was set to avoid injury. The control reaction time and
the latency of the response were recorded two times, with
an interval of 5 min between readings. The mean value of all
trials was considered the tail-flick latency.
2.6.4. Hot-Plate Latency. In the hot-plate test, we measured
the latency to lick a hind-paw when the rat was placed on
a 50∘C plate [45–47]. Rats were placed separately on a plate
enclosed with four plexiglass walls (31 cm × 22 cm × 30
cm), which prohibited the rat from escaping. Rats were then
moved to an adjacent room for the hot-plate test. The rat was
removed from the plate immediately upon licking a hind-paw
or if no response occurred within 50 s. The control reaction
time and the latency of the responsewere recorded twice, with
an interval of 5 min between readings. The mean value of all
trials was considered the hot-plate latency.
2.7. Immunofluorescence and Image Analysis. After the last
behavioral assessment, animals were anesthetized with 1%
pentobarbital sodium (60 mg/kg) intraperitoneally, and
intracardially perfused with 0.1 M phosphate-buffered saline
(PBS), followed by 400–500 mL of 4% paraformaldehyde
(PFA) in PBS. After fixation, rats were decapitated, and the
head was divided into two symmetrical sections along the
sagittal line. Except for the dura mater, all soft tissue was
removed from the inside and outside of the skull. The skull
with the attached dura mater was immersed in 4% PFA and
fixed at 4∘C for an additional 4 h. The skull was subsequently
rinsed and stored in cold PBS. Within the next few days,
the dura mater was removed from the skull using a scalpel
along the edge of the tentorium, SSS, cranial fossa, and TG.
The TG was removed and fixed in 4% PFA /PBS at 4∘C
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overnight, after which it was transferred to 30% sucrose for
72 hours for cryopreservation. Following this, the cranial
dura mater was carefully removed and processed as a whole
mount for staining with an indirect immunofluorescence
technique using a goat anti-CGRP antibody (ab36001, 1:100,
Abcam, Cambridge, UK) and a rabbit anti-VIP antibody
(ab22736, 1:400, Abcam) for 2 days. Rabbit anti-goat or
goat anti-rabbit immunoglobulin G (IgG; 1:200) labeled with
fluorescein isothiocyanate (RAG001, 1:200, MultiSciences
Biotech Co., Ltd, Hangzhou, China) or Alexa 488 (A0432,
1:200, Beyotime Biotech Inc., Shanghai, China) was used as
the secondary antibody for 4 h at 22∘C. The dura sectors
were incubatedwith primary antibodies for 2 dayswith gentle
agitation at 4∘C, following which they were incubated with
secondary antibodies for 4 h at 22∘C. A mixture of 10%
bovine serum albumin with 0.3% Triton X-100 was used
for preincubation (2 h) and rinses (2 h) between incubation
with primary and secondary antibodies. To control for the
uneven distribution of TG neurons, we prepared 3 slides per
animal (20 𝜇m-thick sections/slide) at random. Slides were
incubated with rabbit anti-c-Fos antibody (Ab190289, 1:5000,
Abcam) overnight at 4∘C, and then treated with Cy3-labeled
goat anti-rabbit IgG (H+L) secondary antibodies (A0516,
1:200, Beyotime Biotech Inc.) for 1 h at 22∘C before being
mounted, and cover-slipped in antifade mounting medium
with DAPI (H-1500, Vector Laboratories, Inc., Burlingame,
CA). The images were captured using a Leica semiautomatic
light microscope (Leica DM5500B). The CGRP-positive and
VIP-positive fluorescence images were measured in squares
at 20× magnification, and c-Fos-positive cells were counted
at 40×magnification. Cell and nerve fiber densities in the TG
and dura mater were calculated by a blinded assessor using
Image J software.
2.8. Western Blotting. Rats were anesthetized with 1% pen-
tobarbital sodium (60 mg/kg) intraperitoneally, and the TG
was rapidly removed, placed into 1.8-mL prechilled tubes,
frozen in liquid nitrogen, and stored at -80∘C. For western
blot assays, the TG was collected and homogenized in
radioimmunoprecipitation assay buffer (70-WB019; Multi-
Sciences Biotech Co. Ltd.) using an ultrasonic cell crusher.
The homogenate was centrifuged at 13000 × g for 20 min
at 4∘C, and 300 𝜇L of the supernatant was collected and
stored at -20∘C until analysis. The protein concentrations
of the samples were determined via a bicinchoninic acid
assay using the Micro BCA Protein Assay Kit (Applygen
Technologies Inc., Beijing, China). Proteins were separated
via sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (10% gradient gels), with 50 𝜇g of protein per well,
following which they were transferred to polyvinylidene
difluoride membranes. The polyvinylidene difluoride blots
were blocked in 10% bovine serum albumin for 1 h at 22∘C.
Membranes were incubated with either a rabbit anti-c-Fos
polyclonal antibody (sc-447,1:500, Santa Cruz Biotechnology
Inc, USA) or a mouse glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) monoclonal antibody (C1312, 1:1000,
Applygen Technologies Inc.) overnight at 4∘C. Peroxidase-
conjugated affinipure goat anti-rabbit IgG (H+L), goat anti-
rabbit IgG (H+L) (C1309, 1:10,000, Applygen Technologies
Inc.), or peroxidase-conjugated affinipure goat anti-mouse
IgG (H+L) (C1308, 1:10,000, Applygen Technologies Inc.)
was diluted in 10% bovine serum albumin/Tris-buffered
saline/Tween 20 (TBST) prior to use at 22∘C. All between-
incubation washes were performed using TBST. Signals were
detected using an enhanced chemiluminescence kit (Apply-
gen Technologies Inc.) and Kodak film (Eastman Kodak,
Rochester, NY, USA).The integrated optical density values of
the detected proteins were analyzed using Image J software.
The level of c-Foswas expressed as a ratio toGAPDH(loading
control).
2.9. Sampling and Biochemical Analysis. At the end of all
experiments, animals were deeply anesthetized with 60
mg/kg pentobarbital sodium, and blood samples were col-
lected from the external jugular vein. The samples were then
mixed with ethylenediaminetetraacetic acid, centrifuged at
4000 rpm for 10 min at 4∘C, and stored at −20∘C until
further analysis. Plasma concentrations of SP, CGRP, PACAP,
VIP, NPY, NO, and ET-1 were measured using rat-specific
enzyme-linked immunosorbent assay (ELISA) kits (R&D,
USA; Spibio, USA; Raybio, USA; Aviva Systems Biology,
USA), in accordance with the manufacturer instructions.
2.10. Statistical Analysis. The results were presented as the
means ± standard deviations (SD). All analyses were per-
formed using SPSS version 18.0. Significant differences in the
MWT and TWT were assessed using two-way (time, inter-
vention) repeated-measures analyses of variance (ANOVA).
When the interaction between intervention and time resulted
in a P value less than 0.05, the data were analyzed using a one-
way ANOVA. Multiple comparisons were conducted using
the Bonferroni test (equal variances assumed) or Tamhane
test (equal variances not assumed). In all cases, the level of
statistical significance was set at P<0.05.
3. Results
3.1. Electroacupuncture Attenuated Hyperalgesia in Rats with
Recurrent ConsciousMigraine. In the present study, we inves-
tigated whether EA would alleviate the gradual reductions in
MWT and TWT following DES, and whether EA at multiple
acupuncture points would be more effective at attenuating
hyperalgesia than EA at a single point. To achieve our aims,
we measuredMWTs in the face and hind-paw, as well as hot-
plate and tail-flick latency at least 30 min after EA.
For the facial and hind-paw MWTs, we observed sig-
nificant effects of time (F [4.098]=130.885, P<0.001; F
[3.641]=164.292, P<0.001), and intervention (F [5]=388.387,
P<0.001; F [5]=321.016, P<0.001), and significant interaction
effects between intervention and time (F [20.488]=15.366,
P<0.001; F [18.205]=19.420, P<0.001). On Days 3, 5, 7, and 8,
the facial and hind-paw MWTs were lower in Model group
than in the Sham group (P<0.05). Following EA treatment,
the DES-induced reductions in facial MWTs (GB20+GB34,
P<0.05; GB20, P<0.05; GB34, P<0.05) were significantly
increased on Days 1, 3, 5, 7 and 8, while those in hind-paw
MWTs (GB20 + GB34,P<0.05; GB20, P<0.05; GB34, P<0.05)
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Figure 2: Electroacupuncture (EA) treatment alleviated impairments in the mechanical withdrawal thresholds of the face (a) and hind-paw
(b) and prolonged tail-flick (c) and hot-plate (d) latencies in rats subjected to dural electrical stimulation. Data are presented as the mean
± standard deviation, n=10/group; ∗Sham, GB20+GB34, GB20, and GB34 group vs. Model group (∗P<0.05); # Sham, Non-Acu, GB20, and
GB34 group vs. GB20+GB34 group (#P<0.05).
were significantly increased onDays 3, 5, 7, and 8.Notably, the
elevations in MWTs were greater in the GB20+GB34 group
than in the GB20 (P<0.05) and GB34 (P<0.05) groups on
Days 3, 5, 7, and 8. No significant differences in facial or hind-
paw MWTs were observed between the Non-Acu and Model
groups at any time (all P>0.05; Figures 2(a) and 2(b)).
For tail-flick and hot-plate latencies, we observed sig-
nificant effects of time (F [4.215]=525.886, P<0.001; F [5] =
54.972, P<0.001), and intervention (F [5]=534.624, P<0.001;
F [5]=35.031, P<0.001), and significant interaction effects
between intervention and time (F [21.075]=65.185, P<0.001;
F [25]=5.105, P<0.001). On Days 3, 5, 7, and 8, tail-flick
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and hot-plate latencies were greater in Model group than
in Sham group. Following EA treatment, the DES-induced
reductions in tail-flick (GB20+GB34, P<0.001; GB20, P<0.05;
GB34, P<0.05) and hot-plate (GB20+GB34, P<0.05; GB20,
P<0.05 (on Days 5, 7 and 8); GB34, P>0.05) latencies were
significantly attenuated. Furthermore, the latencies of the
GB20+GB34 group is significantly longer than those of the
GB20 (P<0.05) and GB34 (P<0.05) groups on Days 3, 5,
7, and 8 in the tail-flick test, and than those of the GB34
group (P<0.05) on Days 5, 7, and 8 in the hot-plate test. No
significant differences in tail-flick or hot-plate latencies were
observed between theNon-Acu andModel groups at any time
point (all P>0.05; Figures 2(c) and 2(d)).
Overall, these findings indicated that EA attenuated
hyperalgesia in rats following DES, and that the therapeutic
effects of EA stimulation at GB20+GB34 are superior those
observed for EA at a single point (GB20 or GB34).
3.2. EA Reduced c-Fos Levels in the TG in a Rat Model
of Conscious Migraine. DES induced elevations in c-Fos
expression in the TG. C-Fos expression is regarded as a
biomarker of pain-related behavior, reflecting the degree of
hyperalgesia and the level of activation of the trigemino-
vascular system (TS) [29, 48–50]. To investigate the effects
of EA on hyperalgesia, we performed immunofluorescence
analyses and western blotting to examine the number of
c-Fos-positive cells and levels of c-Fos protein in the TG
(Figure 3). The number of c-Fos-positive cells (Figures 3(a)
and 3(d)) and levels of c-Fos protein (Figures 3(b) and 3(c))
in the TG were significantly more and higher in the Model
group (after repeated DES) than in the Sham group (n=5,
P<0.05 for both). In contrast, the EA-treated groups (except
GB34) exhibited significantly fewer c-Fos-positive cells (n=5,
P<0.05) and significantly lower c-Fos protein levels than
the Model group (n=5, P<0.05), especially the GB20+GB34
group. The c-Fos positive cell numbers and c-Fos protein
levels in the Non-Acu group did not significantly differ from
those in the Model group (P>0.05 for both).
3.3. EA Reduced the Plasma Concentrations of
Vasoactive Neurotransmitters
3.3.1. EA Reduced Plasma Concentrations of CGRP and SP.
The ELISA results revealed that DES (Model group) signif-
icantly elevated the plasma levels of CGRP (Figure 4(a)) and
SP (Figure 4(b)) relative to those observed in the Sham group
(P<0.001 for both). When compared with the levels observed
in the Model group, the plasma levels of CGRP and SP in
the EA-treated (GB20+GB34, GB20, GB34) groups (P<0.001
for all) were significantly reduced; however, no significant
differences in CGRP and SP levels were observed between the
Model and Non-Acu group (P>0.05 for both). Furthermore,
the GB20+GB34 group exhibited significantly lower plasma
levels of CGRP and SP levels than did the GB20 (P<0.05,
P<0.01) or GB34 (P<0.001, P<0.001) group. In addition,
plasma CGRP and SP levels were significantly lower in the
GB20+GB34 (P<0.001) and GB20 (P<0.001) groups than in
the Non-Acu group.
3.3.2. EA Reduced Plasma Concentrations of VIP and PACAP.
To evaluate the effects of EA at GB20+GB34, GB20, and
GB34 on parasympathetic nerve activation in our rat model,
we assessed plasma levels of VIP and PACAP release from
parasympathetic nerves. Our ELISA results indicated that
the Model group had significantly elevated plasma levels
of VIP (Figure 4(c)) and PACAP (Figure 4(d)), relative
to those observed in the Sham group. However, the EA-
treated (GB20+GB34, GB20, GB34) groups exhibited sig-
nificantly reduced plasma VIP and PACAP levels, rela-
tive to those observed in the Model group. No significant
difference in the reduction of plasma VIP concentration
were observed between the GB20 (P<0.01) and GB20+GB34
(P<0.01) groups. And, the reductions in VIP and PACAP
levels were greater in the GB20+GB34 group than in the
GB34 group (P<0.01). No significant difference in the VIP
or PACAP level was identified between the Model and Non-
Acu groups. Furthermore, plasmaVIP levelswere lower in the
GB20+GB34 (P<0.01), GB20 (P<0.01), and GB34 (P<0.01)
groups than in the Non-Acu group.
3.3.3. EA Did Not Affect Plasma Concentrations of NPY.
RepeatedDES did not significantly alter plasma levels of NPY
released from sympathetic nerves (Figure 4(e)). Furthermore,
no significant differences in plasmaNPY levels were observed
among the Non-Acu, GB20+GB34, GB20, and GB34 groups.
3.3.4. EA Attenuated the Plasma Levels of NO and ET-
1. Plasma concentrations of NO (Figure 4(f)) and ET-1
(Figure 4(g)) were significantly higher in the Model group
than in the Sham group (P<0.001). However, the NO and
ET-1 levels of EA-treated groups were significantly lower
than those in the Model group (P<0.001 for all) with no
significant differences in the levels being identified among
the GB20+GB34, GB20, and GB34 groups (P>0.05). Plasma
levels of NO and ET-1 did not significantly differ between the
Non-Acu and Model groups (P>0.05 for both).
3.4. Acupuncture Attenuated the DES-Induced Reductions in
Dural CGRP and VIP Expression. To determine whether EA
influences the expression of vasoactive neurotransmitters in
the dura mater, we performed immunofluorescence analyses
of CGRP and VIP expression.The expression levels of CGRP
and VIP were significantly elevated in Model than that of
Sham group (P<0.001 for both; Figure 5). The CGRP level
in the GB20+GB34 and GB20 groups, but not the GB34
group, was significantly reduced relative to that in the Model
group, while only the GB20+GB34 group showed significant
reductions in the VIP level relative to that in theModel group
(P<0.05; Figure 5). No significant differences in CGRP or
VIP expression were observed between the Model and Non-
Acu groups (P>0.05; Figures 5(b) and 5(d)), or between the
GB20+GB34 and GB20 groups (P>0.05; Figures 5(b) and
5(d)).
4. Discussion
To the best of our knowledge, the present study is the first
to investigate the effects of EA at a single acupuncture point
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Figure 3: The number of c-Fos positive cells (a, d) and levels of c-Fos protein (b, c) were compared in the trigeminal ganglion among the six
groups. Data are presented as the mean ± standard deviation, n=5/group. Scale bar = 50 𝜇m. ∗P<0.05.
(GB20 and GB34 alone) or multiple acupuncture points
(GB20+GB34) on hyperalgesia and vasoactive neurotrans-
mitter release from the perivascular nerves, which includes
the sympathetic, parasympathetic, and sensory nerves, in
a rat migraine model. We found that EA stimulation at
GB20+GB34, GB20, or GB34 reversed mechanical and ther-
mal sensitization, attenuated DES-induced activation of the
trigeminovascular system (c-Fos), and decreased plasma
and dural levels of vasoactive neurotransmitters. Further-
more, it was found that the antihyperalgesia effect of EA
at GB20+GB34 group was better than that of GB20 or
GB34 group. These findings suggested that EA attenuated
hyperalgesia by modulating the release of vasoactive neuro-
transmitters, and that EA at multiple acupuncture points was
more effective than EA at a single point in a rat model of
recurrent migraine.
Our results suggested that EA could improve peripheral
and central sensitization following recurrent DES. Central
and peripheral sensitization is a crucial process underlying
the increases in central and peripheral neuronal excitability
[51]. Central sensitization manifests as hyperalgesia, partic-
ularly dynamic tactile allodynia [52]. Cephalic allodynia is
the presence of sensitization of second-order neurons in the
spinal trigeminal nucleus [53], which can be measured with
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Figure 4: Plasma levels of vasoactive neurotransmitters in the six groups. Vasoactive neurotransmitter release was significantly higher in
Model group rats with migraine than in those of the sham-operated group. Electroacupuncture reduced the release of CGRP (a), SP (b), VIP
(c), PACAP (d), NO (f), and ET-1 (g), while nonacupuncture point treatment had no effect on the levels of these vasoactive neurotransmitters
in rats with migraine. No variations in plasma NPY levels were observed among the six groups. Data are presented as the mean ± standard
deviation, n=10/group. ∗P<0.05. CGRP: calcitonin gene-related peptide; PACAP: pituitary adenylate cyclase-activating polypeptide; NO:
nitric oxide; SP: substance P; NPY: neuropeptide Y; VIP: vasoactive intestinal peptide; ET-1: endothelin-1.
the facial MWT [31, 40]. Moreover, whole-body allodynia
is the presence of sensitization of the thalamus [54], which
can be measured with the hind-paw MWT [31, 40] and hot-
plate [41] and tail-flick latencies [42]. In accordance with
our findings, several previous studies have demonstrated that
repetitive DES results in gradual worsening and spreading
of hyperalgesia [5]. In our study, elevations in the level of c-
Fos protein expression and the number of c-Fos-positive cells
were observed in the TG. Such elevations may be associated
with peripheral sensitization, while reductions in the MWT
and TWT induced by DES may reflect central sensitization.
In addition, the previous researches have indicated that EA
can elicit antihyperalgesic (elevated MWTs) effects in rats
withDES-inducedmigraine [31, 40].Moreover, in the present
study, EA not only increased MWTs, but also improved
TWTs.
Previous researches had suggested that the release of
vasoconstrictive neurotransmitters led to activation and sen-
sitization of the trigeminovascular system [21–23]. Vasoactive
neurotransmitters play a causative role inmigraine, reflecting
a secondary event arising from the activation of trigem-
inal afferents that ensures the meningeal release of addi-
tional vasoactive neurotransmitters [55, 56]. Several studies
have demonstrated that vasodilation neurotransmitters are
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Figure 5: Dural fluorescence intensity of the vasoactive neurotransmitters (CGRP and VIP) in the six groups. Fluorescence intensity for
vasoactive neurotransmitters was significantly higher in Model group rats with migraine than in those of the sham-operated group rats.
Electroacupuncture reduced the intensity of CGRP (yellow arrowheads in (a)) (a, c) and VIP (yellow arrowheads in (b)) (b, d) expression,
while nonacupuncture point treatment had no effect on the levels of these vasoactive neurotransmitters in rats with migraine. The red
arrowheads in (a, b) represent the middle meningeal artery. Data are presented as the mean ± standard deviation, n=5/group. Scale bar
= 50 𝜇m. ∗P<0.05. CGRP: calcitonin gene-related peptide; VIP: vasoactive intestinal peptide.
released upon stimulation of the trigeminal nerve, causing
vasodilation of dural vessels, thereby leading to perivascular
changes, activation/sensitization of the trigeminovascular
system, and the release of vasoactive neurotransmitters
CGRP [12, 57], SP [12, 57], VIP [58], PACAP [59] from the
parasympathetic nerves (sphenopala tine ganglia and otic
ganglia) and sensory nerves (TG, and dorsal root ganglion)
[60]. However, the plasma NPY [58] levels are not changed
from sympathetic nerves (superior cervical ganglia) follow-
ing stimulation of the trigeminal nerve. (Figure 1(c)). During
activation of the trigeminovascular system, CGRP and SP
induce vasodilatation and plasma protein extravasation in
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themeningeal vasculature, leading tomast cell degranulation
followed by peripheral sensitization [61–64]. In addition,
PACAP and NO play key roles in sensitization [65, 66] and
neuroinflammation [67]. Consistent with previous findings,
we observed increases in plasma levels of vasoactive neuro-
transmitters (except NPY) in migraine rats.
The result of the present study suggested that EA can
restore the plasma and dural levels of vasoactive neurotrans-
mitters to normal following DES. We evaluated the plasma
concentrations of CGRP, SP, VIP, PACAP, NPY, NO, and ET-
1 and the dural levels of CGRP and VIP to explore how
EA regulates vasoactive neurotransmitters. Our experiments
revealed that EA significantly reduced the DES-induced
overexpression of CGRP, SP, VIP, PACAP, NO and ET-1 in
recurrent migraine model rats. Similarly, in some studies, EA
reduced the level of SP [68], CGRP [69], VIP [70–72], NPY
[73], NO [74] and ET-1 [75] in plasma or some tissues of other
diseases model animals, including dorsal root ganglion, liver,
synovial, distal colon, spinal cord, hypothalamus, colonic
mucosa, and cardiac tissue. However, we did not observe any
effects of EA on the plasma concentrations of NPY. A possible
reason is that the plasma NPY level did not change fol-
lowing DES. Therefore, EA had a comprehensive regulating
effect on vasoactive neurotransmitters secretion in different
models.
Combinations of multiple acupuncture points are gen-
erally used for the acupuncture treatment of migraine in
clinical practice, especially GB20 and GB34 [28, 32, 34, 35,
76]. Moreover, EA at Waiguan (SJ5) and GB34 decreases
glutamate levels and increases lipid levels in migraine model
rats [77]. Indeed, the vast majority of preclinical studies
focused on the single acupuncture point (GB20). EA at GB20
has been shown to ameliorate the changes in the MWT
by altering c-Fos, 5-HT, 5-HT7R, CGRP, and cannabinoid
1 receptor (CB1R) expression in the descending pathway of
migraine models [29–31, 40, 78]. However, few studies have
investigated the molecular mechanisms underlying EA at
multiple acupuncture points, especially GB20 and GB34. In
our study, it was found that the EA at multiple acupuncture
points was more effective than that at a single point in
attenuating hyperalgesia.
The study had limitations that should be pointed out.
Previous preclinical and clinical studies reported that some
brain regions exhibited atypical functional connectivity in
migraineurs and migraine model rats, including somatosen-
sory pain processing [79] (somatosensory cortex and poste-
rior insula), emotional processing [80] (anterior insula, ante-
rior cingulate cortex, and amygdala), cognitive components
and memories of pain processing [81] (hippocampus and
parahippocampal gyrus), and pain modulation [82] (peri-
aqueductal grey). Moreover, these changes were associated
with the development of hyperalgesia in migraine models
[80]. However, our study only focused on pain modulation.
In future studies, we will evaluate the effects of EA on
the memory and emotional processing of pain. In addition,
previous research has indicated that levels of vasoactive neu-
rotransmitters change dynamically during the development
of migraine-related hyperalgesia [5]. In our study, we only
examined the levels of vasoactive neurotransmitters at the
end of EA treatment.Thus, further studies are required to elu-
cidate the dynamic changes in vasoactive neurotransmitters
that occur during the entire experiment period.
5. Conclusion
Our findings demonstrated that the antihyperalgesic effect
of EA on migraine may be mediated via the modulation of
vasoactive neurotransmitters. In addition, our results support
that EA at multiple acupuncture points may bemore effective
than EA at a single point for relieving hyperalgesia.
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